J. Zablocki

发表

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Synthesis of allopumiliotoxin A alkaloids via iminium ion-vinylsilane cyclizations

L. Overman, J. Zablocki, R. M. Lett, 1988 .

Selective 1D 1H → 13C → 13C polarization transfer experiments for small organic molecules

L. Poppe, J. Zablocki, S. Gröger, 1999 .

Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa.

P. Jacqmin, J. Zablocki, L. Feigen, 1995, Platelets.

Peptide mimetic compounds useful as platelet aggregation inhibitors

M. Toth, J. Zablocki, J. Rico, 1993 .

Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF).

Zhihe Li, P. Ibrahim, Hiba Ahmed, 2004, Bioorganic & medicinal chemistry letters.

Enzymatic Targets in the Triglyceride Synthesis Pathway

J. Zablocki, D. Koltun, 2010 .

Fibrinogen receptor antagonists

J. Zablocki, L. Feigen, N. Nicholson, 1994 .

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

A novel series of orally active antiplatelet agents.

K. Williams, J. Zablocki, J. Rico, 1995, Bioorganic & medicinal chemistry.

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.

A. I. Glushkov, J. W. Chisholm, I. Henderson, 2009, Bioorganic & medicinal chemistry letters.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.

K. Williams, J. Zablocki, J. Rico, 1995, Journal of medicinal chemistry.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.

J. Zablocki, M. Miyano, N. Nicholson, 1993, Journal of medicinal chemistry.

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.

David A. Lustig, S. Kerwar, Xiaofen Li, 2004, Bioorganic & medicinal chemistry letters.

Microwave‐Assisted One‐Step Synthesis of Substituted 2‐Chloromethyl‐1,3,4‐oxadiazoles

J. Zablocki, D. Koltun, R. Natero, 2004 .

Efficient Total Syntheses of Pumiliotoxins A and B. Applications of Iodide-Promoted Iminium Ion−Alkyne Cyclizations in Alkaloid Construction

Leslie A. Robinson, Michael H. Rabinowitz, L. Overman, 1996 .

Enantioselective Total Syntheses of Allopumiliotoxins 267A, 323B‘, and 339A. Application of Iodide-Promoted Iminium Ion−Alkyne Cyclizations for Forming Allopumiliotoxin A Alkaloids

L. Overman, J. Zablocki, M. Sharp, 1996 .

Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.

J. Zablocki, L. Feigen, M. Miyano, 1992, Journal of medicinal chemistry.

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.

David A. Lustig, S. Kerwar, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.

M. Toth, J. Zablocki, J. Rico, 1994, Bioorganic & medicinal chemistry.

Preparation, receptor binding, and fluorescence properties of hexestrol-fluorophore conjugates: evaluation of site of attachment, fluorophore structure, and fluorophore-ligand spacing.

J. Katzenellenbogen, J. Zablocki, T. Fevig, 1987, Journal of medicinal chemistry.

Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use–dependent inhibitor of dopamine synthesis

M. Olive, J. Shryock, N. Chu, 2010, Nature Medicine.

Ketononestrol aziridine, an agonistic estrogen receptor affinity label: study of its bioactivity and estrogen receptor covalent labeling.

B. Katzenellenbogen, J. Katzenellenbogen, J. Zablocki, 1987, Endocrinology.

Estrogenic affinity labels: synthesis, irreversible receptor binding, and bioactivity of aziridine-substituted hexestrol derivatives.

B. Katzenellenbogen, J. Katzenellenbogen, K. Carlson, 1987, Journal of medicinal chemistry.

Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.

A. I. Glushkov, J. W. Chisholm, A. Ivanov, 2009, Bioorganic & medicinal chemistry letters.

Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor.

D. Overstreet, A. Lawrence, B. Vallee, 2009, Alcoholism, clinical and experimental research.

First total synthesis of (+)-allopumiliotoxin 339A. A practical entry to dendrobatid alkaloids of the allopumiliotoxin class

L. Overman, J. Zablocki, L. Robinson, 1992 .

SC-54684A: an orally active inhibitor of platelet aggregation.

J. Zablocki, B. Keller, A. Salyers, 1995, Circulation.

Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.

A. I. Glushkov, M. McGregor, J. W. Chisholm, 2009, Bioorganic & medicinal chemistry letters.

Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists

S. Soelaiman, J. Shryock, L. Belardinelli, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

The Amino-terminal One-third of Defines the Ligand Recognition Specificity of Integrin (*)

Jeffrey W. Smith, J. Zablocki, J. Loftus, 1996, The Journal of Biological Chemistry.

Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use–dependent inhibitor of dopamine synthesis

M. Olive, J. Shryock, N. Chu, 2010, Nature Medicine.